MARSHALL WACE, LLP

Position in ARQT — Arcutis Biotherapeutics, Inc.

CIK 1318757 LONDON, X0

Position in ARQT

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$57,292,689

+$44,101,764 QoQ

Shares Held

2,431,778

+435.4% QoQ

Ownership

1.94%

of shares outstanding

% of Portfolio

0.08%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2020

11 quarters on record

Voting authority Sole 0.ToString("F0")% Shared 100.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

MARSHALL WACE, LLP holds $2,749,797,393 across 275 Biotechnology names. ARQT ranks #9 (2.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	1,099,318	$363,731,344
2	VRTX	Vertex Pharmaceuticals Inc / Ma	317,058	$141,579,078
3	INCY	Incyte Corp	1,253,138	$117,945,347
4	RPRX	Royalty Pharma plc	2,120,692	$101,729,594
5	RCUS	Arcus Biosciences, Inc.	3,761,437	$81,247,039
6	PTGX	Protagonist Therapeutics, Inc	628,075	$66,199,104
7	ROIV	Roivant Sciences Ltd.	2,246,943	$62,240,320
8	COGT	Cogent Biosciences, Inc.	1,600,168	$61,590,466

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$57,292,689	2,431,778	+435.4%	Shares	Other	2026-05-15
2025-12-31	$13,190,925	454,233	+2382.1%	Shares	Other	2026-02-13
2025-09-30	$344,955	18,300	-68.4%	Shares	Other	2025-11-13
2025-03-31	$905,681	57,908	-39.1%	Shares	Other	2025-05-15
2023-12-31	$306,885	95,011	-95.9%	Shares	Other	2024-02-14
2023-09-30	$12,271,818	2,311,077	-0.3%	Shares	Other	2023-11-14
2023-06-30	$22,086,165	2,317,541	+0.5%	Shares	Other	2023-08-14
2023-03-31	$25,358,696	2,305,336	+1273.7%	Shares	Other	2023-05-15
2022-09-30	$3,206,963	167,816	-1.0%	Shares	Other	2022-11-14
2021-03-31	$4,903,258	169,487	+114.6%	Shares	Other	2021-05-17
2020-12-31	$2,221,510	78,973	—	Shares	Sole	2021-02-16
No filing history on record for this holder in this stock.